Pacira BioSciences, Inc., a leader in non-opioid pain therapies, has announced promising preliminary data regarding its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), for osteoarthritis of the knee. The findings, presented at the American Society of Gene & Cell Therapy Annual Meeting, indicate that clinical immunogenicity does not diminish the sustained improvements in knee pain, stiffness, and function following local administration of PCRX-201. The study suggests that pre-existing and treatment-induced anti-Ad5 neutralizing antibodies do not affect the safety or effectiveness of the therapy. This development is part of Pacira's ongoing Phase 2 study and aligns with their 5x30 strategy for growth, aiming to provide long-lasting pain relief for the 14 million individuals affected by knee osteoarthritis. PCRX-201 previously received Regenerative Medicine Advanced Therapy designation from the FDA, and the new data supports its potential as an effective and durable treatment alternative to current short-term therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.